Released Aug 5, 2025, before the open
10-Q filed Aug 5, 2025, 36 days after period end · 0000950170-25-102384
Q2 2025 · 10-Q
Revenue$203.12M$203.12M +2.3% vs Q2 2024+4.9% vs Q1 2025
Net Income-$14.08M-$14.08M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.36-$0.36 N/M vs Q2 2024N/M vs Q1 2025
Gross Profit$139,533,000+3.6%
Operating Income-$16,003,000N/M
Operating Cash Flowderived$11,639,000+29.6%
Free Cash Flowderived$4,530,000N/M
Margins · derived
Gross margin68.7%+0.9 pt vs Q2 2024
Operating margin-7.9%+4.7 pt vs Q2 2024
Net margin-6.9%+9.9 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $203.12M | $198.62M | $187.02M | $118.07M |
| Net Income | -$14.08M | -$33.44M | -$39.43M | $2.49M |
| EPS Diluted | -$0.36 | -$0.88 | -$1.07 | $0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR